UNITEDHEALTH GROUP INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $UNH in the last 30 days.
See all $UNH insider activity →UnitedHealth Group (UNH) reported Q3 2026 earnings of $4.69 per share, beating estimates by $0.55. The company raised its 2026 earnings guidance to at least $20.50 per share, up from the consensus of $19.87. Revenues were $112.7 billion, slightly down year-over-year but above projections. UNH offers a 2.29% dividend yield with a 52% payout ratio and a GF Score™ of 84, indicating strong fundamentals.
UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.
Wall Street analysts highlight growth prospects for UnitedHealth (UNH), Meta Platforms (META), and Marvell Technology (MRVL). UNH raised earnings outlook; Morgan Stanley targets $529. META's Muse AI gains traction; Guggenheim raises target to $850. MRVL expands AI market estimate; Stifel targets $370.
Over the past 7 days, AlphAI's AI scored 162 news stories mentioning UNH (UNITEDHEALTH GROUP INC). Coverage has skewed bullish: 111 bullish, 32 neutral, and 19 bearish.
Recent UNH coverage spans earnings, financial news and regulation.
Guidance raise signals stronger earnings outlook, likely supporting price appreciation.
Guidance lift suggests higher earnings expectations.
Analyst upgrade with higher EPS estimate and price target.
Opposition suggests potential friction in adoption, but without disclosed details it is more headline risk than a direct financial change.
Improving medical cost metrics and raised 2026 guidance support further upside, but falling membership and Medicare Advantage quality pressure add downside risk to the durability of the turnaround.
AlphAI scores every news story that mentions UNH with an AI model for sentiment and relevance, and aggregates insider trades from UNITEDHEALTH GROUP INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
UnitedHealth Group (UNH) reported Q3 2026 earnings of $4.69 per share, beating estimates by $0.55. The company raised its 2026 earnings guidance to at least $20.50 per share, up from the consensus of $19.87. Revenues were $112.7 billion, slightly down year-over-year but above projections. UNH offers a 2.29% dividend yield with a 52% payout ratio and a GF Score™ of 84, indicating strong fundamentals.
2 min readUnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.
3 min readWall Street analysts highlight growth prospects for UnitedHealth (UNH), Meta Platforms (META), and Marvell Technology (MRVL). UNH raised earnings outlook; Morgan Stanley targets $529. META's Muse AI gains traction; Guggenheim raises target to $850. MRVL expands AI market estimate; Stifel targets $370.
3 min readVerizon, UnitedHealth, and Broadcom oppose tokenizing their shares under a new regulatory framework, according to The Wall Street Journal. Stock tokenization involves representing share rights as blockchain-based tokens. The companies' reasons for opposition were not disclosed.
2 min readUnitedHealth Group reported Q3 2026 adjusted earnings of $4.69 per share, beating estimates and raising its annual outlook to at least $20.50 per share. Revenues were $112.7 billion, with improved margins but declining membership. Optum's earnings rose despite revenue declines. Analysts revised earnings estimates higher, but challenges include medical utilization and Medicare Advantage ratings.
7 min readUnitedHealth Group (UNH) raised its 2026 EPS outlook to $20.50, citing growth in Optum Health, its care division. Optum Health serves 20M patients, with 4M in fully accountable relationships, leaving room for expansion. It generated 22.8% of UNH's 2025 revenue but saw a 3.2% revenue decline. UNH's stock rose 16.0% YoY, lagging the S&P 500. Management targets 6-8% margins for Optum Health, a multi-year effort.
3 min readSPDR Dow Jones Industrial Average ETF (DIA) sold $309.2M in stocks on Oct. 14, reducing all 30 holdings. Largest sales were GS ($31.3M), CAT ($26.7M), and MSFT ($19.0M). DIA manages $44.93B with a 0.16% expense ratio and a 9.64% YTD return. No new positions were opened.
2 min readBernstein reduced its price target for UnitedHealth Group from $512 to $500. The stock's pre-market price was $406.67, up 2.79%. The adjustment is based on valuation, earnings revisions, and visibility metrics.
1 min readAI stocks faced volatility, prompting capital rotation into pharmaceuticals. Eli Lilly (LLY) and AbbVie (ABBV) neared record highs, with LLY at $1,251.61 and ABBV at $283.40. Healthcare ETF XLV hit $177.19. LLY's gains were driven by its GLP-1 dominance and M&A activity, while ABBV's rally followed positive Skyrizi data. Other large-cap pharma stocks also rose, but biotech ETF XBI declined 2.8% over a month.
3 min readBWX Technologies (BWXT), Johnson & Johnson (JNJ), and UnitedHealth Group (UNH) raised FY26 guidance following strong quarterly results. BWXT reported 18% revenue growth and raised EPS guidance to $4.70–$4.80. JNJ saw 5.9% sales growth and increased EPS outlook to $11.10. UNH improved cost trends and raised EPS guidance to at least $20.50.
6 min read
